l*h
发帖数: 4124 | 1 ponatinib, a star pathway targeting agent, has been suspended by FDA. |
|
s******i
发帖数: 350 | 2 http://www.news-medical.net/news/20120618/Updated-data-from-ARI
"The pivotal PACE trial data show robust anti-leukaemic activity of
ponatinib in patients with CML at all stages, who are resistant or
intolerant to dasatinib or nilotinib, or who have the T315I mutation, a rare
form of CML which has no available treatment options," said Jane F.
Apperley, professor and chair, Department of Haematology at the Imperial
College, and the chief of service, Clinical Haematology, at the Imperial
College He... 阅读全帖 |
|
l********e
发帖数: 413 | 3 来自主题: Pharmaceutical版 - 这是什么药？ A new drug called ponatinib (Iclusig:emoji:) may be a new treatment option
for patients withchronic myeloid leukemia(CML) that is resistant to other
therapies, researchers said December 9, 2012, at the American Society of
Hematology (ASH)annual meetingin Atlanta. Patients with a type ofacute
lymphoblastic leukemia(ALL) that resists current treatments may also benefit
from ponatinib.
请问ponatinib中文名是什么？谢谢。 |
|
m******c
发帖数: 1202 | 4 Ever since Ariad Pharmaceuticals’ Ponatinib treatment for leukemia was
given the green light by American regulator, the FDA, industry majors have
been sniffing around. As its shares changed hands at $6.50, valuing the
Massachusetts-based company at around £800m, dealers heard whispers
from across the Pond that at least three international pharma groups
including US giant Eli Lilly have made ‘friendly approaches’ to the Ariad
board and are prepared to pay up to $20 a share in cash to gain co... 阅读全帖 |
|
l*h
发帖数: 4124 | 5 Ponatinib is a new drug approved for patients with Ph+ ALL. Preliminary
results show it is superior to other tyrosine kinase inhibitors in Ph+ ALL.
It should not be available in China now.
Imatinib, dasatinib etc should be easier to obtain.
Dose scaling in pediatric patients of tyrosine kinase inhibitors: should be
based on body surface area, not on body weight.
L |
|
l*h
发帖数: 4124 | 6 Ponatinib is a new drug approved for patients with Ph+ ALL. Preliminary
results show it is superior to other tyrosine kinase inhibitors in Ph+ ALL.
It should not be available in China now.
Imatinib, dasatinib etc should be easier to obtain.
Dose scaling in pediatric patients of tyrosine kinase inhibitors: should be
based on body surface area, not on body weight.
L |
|
c******r
发帖数: 74 | 7 谢谢你，Lmh，Ponatinib 是否在美国需要处方才能买到，或者在欧洲能不能买到？
you
20
unbelievable |
|
s******i
发帖数: 350 | 8 ARIA is partnered with Merck. From phase 3 clinical trial, its new drug
Ponatinib has significant efficacy to treat leukemia. The side effect is
small. The potential market is very promising. |
|
l********i
发帖数: 2503 | 9 ARIAD expects to file for regulatory approval of ponatinib in the EU and in
the U.S. in Q3 of 2012 based on these clinical data.
在９月３０日前尽量BUY DIP。 |
|
|
|
s******t
发帖数: 213 | 12 ARIAD Announces U.S. Resumption of Marketing and Commercial Distribution of
Iclusig (ponatinib) in Refractory Philadelphia-Positive Leukemias |
|
E**********r
发帖数: 2743 | 13 (turkey FA, YMYD)
可以关注下SYN （Biologics Inc.），貌似也会涨。
Biologics, Inc., an integrated oncology services company, is pleased to
announce that it has been selected by ARIAD Pharmaceuticals, Inc. (ARIA) to
be the sole specialty pharmacy provider of Iclusig® (ponatinib) and
manager of its Patient Access and Support Services (ARIAD PASSTM) program.
。。。
http://finance.yahoo.com/news/biologics-selected-ariad-exclusiv |
|
b*****r
发帖数: 2065 | 14 大牛觉得Aria 的Ponatinib和诺华的一线药格列卫相比有什么可比性吗？ |
|
b*****r
发帖数: 2065 | 15 ARIA的Ponatinib是新一代的治疗CML的药，这个药起码能使用20年，FDA也准了，现在
的问题就是卖了，一个病人的价值是24万美金，美国一年可以有2600个病人。欧洲也差
不多这个数字，其他地区算1500个。一年估计在6000病人，这个药一年的销售额在120M
左右。
收购也是完全可能的，诺华的格力卫2013年专利到期，必须有其他专利药替代， 生物
药没有那么快能开发出来的。收购的消息很可能是真的，另外据传，上次24跌到2元多
的时候，管理层为担心恶意收购已经上了毒丸计划，以防止恶意收购，如果这次收购价
在20元左右，管理层完全可能愿意谈好这个deal。小药股的一个命运就是被收购。 大
到健赞也被法国的那个叫什么来着收购了，Genetech也一样被罗氏收购。BIIB很可能也
是这个命运， GILEAD也许能独立经营下去， CELG被收购就是一个时间问题。 |
|
|
f**********g
发帖数: 2252 | 17 Got it. Good news on 5/4 ER.
Ariad Pharmaceuticals (ARIA) based in Cambridge, MA, engages in the
discovery and development of small-molecule drugs for the treatment of
cancer. On Wednesday evening, the company released its 1Q 2011 earnings and
hosted a conference Thursday morning discussing the report. Much of the
report was expected; however, management announced that the pivotal phase 2
trial for ponatinib, called PACE, was on track for significantly early
enrollment (six months early!). This ... 阅读全帖 |
|
y*****l
发帖数: 5997 | 18 11:55 Do you think there is > 50% chance someone buys HGSI in next 12 mos.?
Yes
( 68% )No
( 32% )
Thursday October 20, 2011 11:55
11:56 adam feuerstein: Hello! Welcome to the October edition of Biotech
Stock Live Chat.
Thursday October 20, 2011 11:56 adam feuerstein
12:02 adam feuerstein: hi everyone
Thursday October 20, 2011 12:02 adam feuerstein
12:02 adam feuerstein: I'll get started in a minute or so, let folks log in
.
Thursday October 20, 2011 12:02 adam feuerstein
12:02 adam feuers... 阅读全帖 |
|
